[Four cases of bevacizumab-related gastrointestinal perforation].
We report 4 cases of gastrointestinal perforation associated with systemic administration of bevacizumab. Case 1: A 51- year-old man with colorectal cancer (CRC) received mFOLFOX+bevacizumab (Bev). A small intestinal perforation occurred 7 days after Bev administration (Bev-a) and was successfully treated with omental packing. Case 2: A 50-year-old woman with CRC received capecitabine+Bev. A small intestinal perforation was detected 5 days after Bev-a, and was successfully treated with primary suture and an omental flap. Case 3: A 74-year-old man with CRC received CapeOX+Bev. A duodenal perforation occurred on the same day as Bev-a, but could be treated conservatively. Case 4: A 57-year-old man with lung cancer received DTX+Bev. A small intestinal perforation occurred 13 days after Bev-a, but this could be managed with primary suture and an omental flap. The gastrointestinal perforation presented with mild abdominal pain and was detected within 14 days after Bev-a in each of these 4 cases. Three patients were successfully treated with only minimal surgical procedures and 1 patient could be managed with conservative treatment for a perforated duodenal ulcer.
Dept. of Gastroenterological Surgery, Aichi Medical University Hospital.
Tairin
T
Uchino
Hideyuki
H
Mishima
Kengo
K
Kimura
Daiki
D
Mori
Keiichi
K
Ando
Hiroshi
H
Nagata
Riki
R
Kondo
Kenshi
K
Kosaka
Norifumi
N
Ohashi
Nobuhiro
N
Ito
Takashi
T
Arikawa
Masahiko
M
Miyachi
Kazuyoshi
K
Suzumura
Tsuyoshi
T
Sano
Toshiaki
T
Nonami
D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced / Q000601:surgery* / Q000628:therapy; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab